Sermorelin: Dosing & Research Guide

Overview

What is Sermorelin?

Sermorelin is the first 29 amino acids of your body's natural GHRH (growth hormone releasing hormone), and that's all it takes. Researchers found that all of GHRH's biological activity lives in those first 29 amino acids — the rest is dead weight. Serono Laboratories got it FDA-approved in 1997 as Geref for diagnosing and treating growth hormone deficiency in kids.

Sermorelin stimulates the pituitary gland to produce and secrete growth hormone through GHRH receptor activation on somatotroph cells. Here's the big advantage over injecting straight GH: Sermorelin lets your body decide how much growth hormone to make. It preserves the natural pulsatile release pattern and keeps the feedback loop intact. Your own regulatory system prevents GH from going dangerously high — a built-in safety margin you don't get with exogenous GH.

Geref was pulled from the market in 2008 for business reasons, not safety reasons. Sermorelin is alive and well in compounding pharmacies and research settings. Few GH secretagogues can match its track record: years of clinical use, actual FDA approval history, and a thoroughly characterized safety profile. It is frequently used in age-management medicine as an alternative to direct GH replacement.

Science

Mechanism of Action

Sermorelin's mechanism of action centers on its interaction with the GHRH receptor on pituitary somatotroph cells. As a truncated analog of native GHRH, it retains full receptor binding affinity and triggers the same downstream signaling cascade that promotes growth hormone synthesis and release.

GHRH Receptor Activation

Sermorelin binds to the GHRH receptor (GHRHR), a G-protein coupled receptor on the surface of anterior pituitary somatotroph cells. This activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors including CREB (cAMP response element-binding protein), ultimately driving GH gene transcription and hormone release [1].

Pulsatile GH Release

Unlike exogenous GH administration, which creates continuous supraphysiological levels, Sermorelin stimulates the pituitary to release GH in the body's natural pulsatile pattern. This is physiologically significant because GH pulsatility is required for many of its downstream effects, including hepatic IGF-1 production and proper metabolic signaling. The hypothalamic-pituitary feedback loop remains intact, with somatostatin continuing to regulate pulse frequency and amplitude [3].

Somatotroph Proliferation

Chronic GHRH stimulation has been shown to promote somatotroph cell proliferation and GH mRNA expression. This is clinically relevant in aging populations where pituitary GH reserve declines. Sermorelin may help restore pituitary responsiveness over time, a phenomenon observed in long-term clinical studies where GH responses to GHRH testing improved after several months of treatment [4].

IGF-1 Axis Activation

The GH released by Sermorelin stimulation acts on the liver and peripheral tissues to produce insulin-like growth factor 1 (IGF-1). IGF-1 mediates many of the anabolic effects attributed to growth hormone, including protein synthesis, bone mineral density maintenance, and tissue repair. Sermorelin-stimulated IGF-1 elevation is dose-dependent and remains within physiological ranges due to preserved negative feedback.

Dosing

Dosing Protocol

Sermorelin dosing in both clinical and research settings has been well-established through its years of FDA-approved use. The standard approach emphasizes bedtime administration to capitalize on the natural nocturnal GH surge.

Protocol	Dose	Frequency	Duration	Notes
Standard	200–300 mcg	Once daily at bedtime	3–6 months	Capitalizes on nocturnal GH surge
Twice daily	100–200 mcg	AM fasted + bedtime	3–6 months	Two GH pulses per day
With GHRP	100 mcg + 100 mcg Ipamorelin	2–3x daily	3–6 months	Synergistic GHRH+GHRP approach
Continuous	200–300 mcg	Once daily	6+ months	Some protocols use continuously; longer cycles typical

Dosing Notes
Always inject on an empty stomach. Food — particularly fats and carbohydrates — significantly blunts GH release by raising blood glucose and insulin.
Bedtime dosing is preferred because it amplifies the natural nocturnal GH pulse that occurs during deep sleep.
For twice-daily protocols, the morning dose should be given fasted, at least 30 minutes before eating.
Results from Sermorelin typically become noticeable after 3–6 months of consistent use. Initial improvements in sleep quality are often reported within the first few weeks.

Preparation

Reconstitution Guide

Reconstitute the Sermorelin with bacteriostatic water. It dissolves easily. Don't shake.

Remove the plastic cap from the Sermorelin vial and wipe the rubber stopper with an alcohol swab. Allow to dry completely.
Draw the appropriate volume of bacteriostatic water into a sterile syringe. For a 5 mg vial, use 2 mL for a concentration of 2,500 mcg/mL. For a 10 mg vial, use 2 mL for 5,000 mcg/mL.
Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.

5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg/mL

200 mcg dose = 8 units (0.08 mL) on a 100-unit insulin syringe

300 mcg dose = 12 units (0.12 mL) on a 100-unit insulin syringe

10 mg vial + 2 mL BAC water: Concentration = 5,000 mcg/mL

200 mcg dose = 4 units (0.04 mL) on a 100-unit insulin syringe

Doses per 5 mg vial: 25 doses at 200 mcg, or 16 doses at 300 mcg

Supplies Needed (3-Month Cycle at 300 mcg/day)
6 vials Sermorelin (5 mg each) — provides ~100 doses, covers 90 days with margin
3 vials bacteriostatic water (30 mL each)
90 insulin syringes (29–31 gauge, 100-unit)
Alcohol prep pads

Administration

Injection Technique

Sermorelin is administered via subcutaneous (SubQ) injection. This is the standard route for peptide self-administration, providing consistent absorption and ease of use.

Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or back of the upper arm.
Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45- to 90-degree angle in a quick, smooth motion. Release the skin fold.
Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.

Timing Considerations

Sermorelin should be injected at least 30 minutes after the last meal of the day, ideally right before bed. Elevated blood glucose and insulin suppress GH release and will significantly reduce the effectiveness of the injection. Avoid eating after the injection.

Storage

Storage & Stability

Sermorelin has good stability among peptides, but proper storage practices are essential to maintain potency throughout the cycle.

Lyophilized (Powder)

2–8°C (36–46°F)

Refrigerator. Stable for 24+ months sealed.

Lyophilized (Long-term)

-20°C (-4°F)

Freezer. Extended stability beyond 2 years.

Reconstituted

2–8°C (36–46°F)

Refrigerate immediately. Use within 30 days.

Avoid

Do not freeze reconstituted solution

Freezing causes peptide degradation and aggregation.

Storage Tips
Store vials upright, out of direct light.
If you see condensation on a cold vial, let it warm to room temp before opening — moisture getting inside is bad news.
Never re-freeze a reconstituted vial. If it sat out at room temp for more than 4 hours, toss it.
Pro tip: label each vial with the date you reconstituted it so you know when the 30-day clock runs out.

Safety

Side Effects & Considerations

Sermorelin has one of the longest clinical safety records among GH secretagogues, derived from its years of FDA-approved use (1997–2008). Its discontinuation was for commercial reasons, not safety concerns.

Commonly Reported

Injection site reactions — redness, pain, and swelling at the injection point. The most common side effect, usually mild and transient.
Facial flushing — a brief warmth or redness of the face immediately after injection, resolving within minutes.
Headache — particularly during initial use, typically diminishing with continued treatment.
Dizziness or lightheadedness — reported infrequently, more common in the first week.

Less Common

Difficulty swallowing — rare, reported in clinical trials at low incidence.
Hyperactivity or restlessness — occasionally reported, especially with evening dosing.

Clinical Safety Profile

Does not suppress the hypothalamic-pituitary-adrenal (HPA) axis at standard doses.
No tachyphylaxis (loss of response) has been observed with long-term use — a key advantage over some other secretagogues.
Preserves natural GH feedback, preventing supraphysiological hormone levels.
No evidence of antibody formation affecting efficacy in clinical use.

Important

Sermorelin is classified as a research peptide when obtained outside of a clinical prescription. Everything here comes from published clinical and preclinical research and is not medical advice or a treatment recommendation. Always inject on an empty stomach; food blunts GH release significantly.

Protocols

Stacking Protocols

Sermorelin is frequently combined with growth hormone releasing peptides (GHRPs) for synergistic GH pulse amplification. GHRH and GHRP act through distinct receptor pathways, and their combined effect on GH release is greater than the sum of either alone.

Sermorelin + Ipamorelin (GH Optimization Stack)

The most common combination in research and clinical practice. Sermorelin provides the GHRH stimulus while Ipamorelin provides the GHRP stimulus, creating a robust, synergistic GH pulse. Ipamorelin is preferred as the GHRP component because it does not significantly raise cortisol or prolactin.

Peptide	Dose	Frequency	Duration
Sermorelin	100–200 mcg	2–3x daily (fasted)	3–6 months
Ipamorelin	100–200 mcg	2–3x daily (with Sermorelin)	3–6 months

Sermorelin + CJC-1295 (Extended Release Stack)

CJC-1295 with DAC provides a sustained GHRH signal (half-life ~8 days), while Sermorelin provides acute pulsatile stimulation. This combination aims to elevate baseline GH levels while maintaining natural pulse dynamics.

Peptide	Dose	Frequency	Duration
Sermorelin	200–300 mcg	Once daily at bedtime	3–6 months
CJC-1295 (DAC)	2 mg	Once weekly	3–6 months

Lifestyle Factors

The following factors significantly influence GH secretion and should be optimized during Sermorelin protocols:

Sleep: Growth hormone release peaks during deep (Stage 3) sleep. Prioritize 7–9 hours and maintain consistent sleep timing.
Fasting state: Elevated blood glucose and insulin suppress GH release. Avoid eating for at least 2 hours before the bedtime injection.
Exercise: Resistance training and high-intensity interval training independently stimulate GH release. Exercise earlier in the day to compound effects.
Body composition: Excess visceral fat is associated with reduced GH secretion. Weight management supports pituitary responsiveness to GHRH stimulation.

If you're interested in Sermorelin these are worth checking out too:

References

Literature & Citations

Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PubMed
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PubMed
Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. PubMed
Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed
Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993;14(1):20-39. PubMed
Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PubMed
Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans. J Clin Endocrinol Metab. 1999;84(2):531-535. PubMed

Sermorelin